Rockwell Medical (NASDAQ:RMTI) Stock, Quote.Headers.trade-ideas

Rockwell Medical

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.

Earnings

Equities

News

Penny Stocks

Guidance

Small Cap

Markets

Movers

RMTI

Rockwell Medical Inc (NASDAQ: RMTI) reported a Q2 FY23 revenue of $18.1 million, 

Why Rockwell Medical Shares Are Surging Today

Intraday Update

Trading Ideas

ABOS

ALNY

APLS

ARDS

ARGX

AWIN

BBIO

BCAN

BLBX

CJET

CNSL

CVGW

EVGN

EVGO

FTCH

FYBR

GBNH

GNPX

HCTI

JZXN

KSCP

LIXT

MNPR

NOVN

NVFY

PRDS

PRFX

PUYI

RKDA

STGW

SXTP

TIVC

UPST

UTME

UTRS

VIRI

VRAY

WAVS

YELP

ZIMV

ZLAB

Gainers


	ProMIS Neurosciences, Inc.  (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer&#39;s Association International Conference 2023 on computationally-derived antibody and vaccine from Alzheimer&#39;s pipeline.


Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Analyst Color

Health Care

Price Target

Reiteration

Analyst Ratings

General

Rockwell Medical On Course To Reach Profitability By Late 2024, Analyst Says

Rockwell Medical Inc

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and maintains $9 price target.

HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $9 Price Target

WIIM

Rockwell Medical shares are trading higher after the company announced it secured a major deal to supply dialysis products for at-home and acute care.

Rockwell Medical, Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced a product purchase agreement with the leading at-home and acute care dialysis provider in the United States (the "Customer"). Under the terms of the agreement, Rockwell Medical will supply the Customer with the Company's liquid acid RenalPure&#xAE; and liquid bicarbonate SteriLyte&#xAE;, both of which will be packaged in either the Company's four-per-case packaging for larger dialysis settings or two-per-case packaging for smaller acute care and at-home care settings.

Rockwell Medical Secures Major Deal to Supply Dialysis Products for At-Home and Acute Care

Rockwell Medical shares are trading higher after the company announced a distribution agreement with Nipro Medical.

The agreement will remain in effect for two years with the option to extend the agreement for an additional one-year period and includes product purchasing minimums of $5.0 million for the first year and incremental increases each subsequent year.&nbsp;

Contracts

Rockwell Medical Announced A Distribution Agreement With Nipro Medical, To Supply Liquid And Dry Acid And Bicarbonate Hemodialysis Concentrates, As Well As Its Dry Acid Concentrates Mixer, For Which Nipro Has The Right To Distribute Rockwell's Products Globally, Excluding US

Rockwell Medical shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates.

GUIDANCE
Rockwell Medical updates its 2024 guidance as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Updated&nbsp; 2024 Guidance&nbsp; (As of August 8, 2024)</td>
<td colspan="1" rowspan="1">Updated&nbsp; 2024 Guidance&nbsp; (As of May 14, 2024)</td>
<td colspan="1" rowspan="1">Original&nbsp; 2024 Guidance&nbsp; (As of March 21, 2024)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net (Product) Sales</td>
<td colspan="1" rowspan="1">$95.0M to $98.0M</td>
<td colspan="1" rowspan="1">$90.0M to $94.0M</td>
<td colspan="1" rowspan="1">$84.0M to $88.0M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Profit</td>
<td colspan="1" rowspan="1">$14.0M to $16.0M</td>
<td colspan="1" rowspan="1">$13.0M to $15.0M</td>
<td colspan="1" rowspan="1">$12.0M to $14.0M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">14% to 17%</td>
<td colspan="1" rowspan="1">14% to 16%</td>
<td colspan="1" rowspan="1">14% to 16%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$0.75M to $1.5M</td>
<td colspan="1" rowspan="1">$0.5M to $1.0M</td>
<td colspan="1" rowspan="1">$0M to $0.5M</td>
</tr>
</tbody>
</table>
</figure>

Rockwell Medical Projects Net Sales To Grow In The Mid-to-high Single Digits In 2025 And Beyond, And Gross Margin In 2025 To Be Approximately 20% And Reaching Above 25% In 2026 And Beyond

Rockwell Medical Expects 2024 Sales Of $95.0M-$98.0M Compared To Prior Guidance Of $90.0M-$94.0M And Consensus Of $92.494M

Rockwell Medical Q2 2024 Adj. EPS $0.05 Beats $(0.04) Estimate, Sales $25.800M Beat $22.921M Estimate

Rockwell Medical Announced That It Has Launched A Convenience Pack, Which Includes Two 1-gallon Pre-mixed Containers Of One Of The Company's Hemodialysis Concentrate Products CitraPure, RenalPure, or SteriLyte

Rockwell Medical Raises FY24 Net Sales Outlook To $90.0M-$94.0M Vs. $88.97M Estimate (Prior View: $84.0M-$88.0M);  Projects Net Sales To Grow In The Mid-to-high Single Digits In 2025 And Beyond

Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. This is a 80 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $22.68 million which beat the analyst consensus estimate of $21.70 million by 4.50 percent. This is a 15.29 percent increase over sales of $19.67 million the same period last year.

Earnings Beats

Rockwell Medical Q1 Adj $(0.02) Beats $(0.04) Estimate, Sales $22.68M Beat $21.70M Estimate

<h3>Gainers</h3>
<ul>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) shares moved upwards by 23.3% to $0.57 during Monday's after-market session. The market value of their outstanding shares is at $27.0 million. </li>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) shares rose 13.5% to $13.7. The market value of their outstanding shares is at $484.7 million. As per the press release, Q1 earnings came out today. </li>
<li>Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) stock moved upwards by 12.19% to $0.92. The market value of their outstanding shares is at $162.6 million. The company's, Q1 earnings came out today. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) shares moved upwards by 7.77% to $1.94. The market value of their outstanding shares is at $60.1 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock moved upwards by 6.94% to $0.77. The market value of their outstanding shares is at $174.1 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock moved upwards by 6.43% to $6.48. The company's market cap stands at $69.7 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Augmedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUGX#NASDAQ">AUGX</a>) shares fell 33.8% to $1.55 during Monday's after-market session. The company's market cap stands at $75.8 million. The company's, Q1 earnings came out today. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock decreased by 19.91% to $3.3. The market value of their outstanding shares is at $162.9 million. As per the press release, Q1 earnings came out today. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares fell 5.0% to $0.21. The market value of their outstanding shares is at $10.3 million. </li>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock declined by 4.81% to $3.37. The company's market cap stands at $184.1 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) stock decreased by 4.71% to $1.62. The company's market cap stands at $47.5 million. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) stock declined by 4.08% to $4.0. The market value of their outstanding shares is at $103.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKYA

AUGX

CLDI

ELEV

GOSS

HROW

LTRN

MODD

NOTV

VXRT

12 Health Care Stocks Moving In Monday's After-Market Session

Rockwell Medical Announced Product Purchase Agreement With US Health Systems In The Mountain West Region To Supply Its Liquid And Dry Acid And Bicarbonate Hemodialysis Concentrates, Cleaning Agents, And Hemodialysis Concentrates Mixers

In the aggregate, these agreements are expected to generate approximately&nbsp;$1 million&nbsp;in annual revenues for the Company.&nbsp;The amended distribution agreement between Rockwell Medical and AMI expands the list of hemodialysis products that AMI is purchasing from the Company, includes purchasing commitments, and generates a profit margin consistent with Rockwell Medical&#39;s gross margin&nbsp;guidance&nbsp;for 2024.

Rockwell Medical Enters New And Expanded Distribution Agreement With BioNuclear And Atlantic Medical International

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and lowers the price target from $11 to $9.

HC Wainwright & Co. Maintains Buy on Rockwell Medical, Lowers Price Target to $9

<h3>Gainers</h3>
<ul>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares rose 33.9% to $0.83 during Friday's after-market session. The market value of their outstanding shares is at $3.2 million. </li>
<li>Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) shares rose 12.48% to $151.77. The company's market cap stands at $8.0 billion. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares moved upwards by 11.17% to $0.38. The market value of their outstanding shares is at $66.7 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock moved upwards by 11.11% to $2.2. The company's market cap stands at $8.0 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock increased by 9.09% to $1.2. The company's market cap stands at $16.0 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares rose 8.02% to $0.29. The company's market cap stands at $53.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) shares declined by 9.5% to $1.72 during Friday's after-market session. The market value of their outstanding shares is at $47.9 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares declined by 7.02% to $1.59. The market value of their outstanding shares is at $46.3 million. The company's, Q4 earnings came out yesterday. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares fell 6.49% to $2.02. The company's market cap stands at $204.9 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) stock declined by 6.36% to $0.43. The market value of their outstanding shares is at $7.8 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares decreased by 6.03% to $0.42. The company's market cap stands at $6.7 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) stock fell 5.93% to $2.54. The market value of their outstanding shares is at $21.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGXX

MASI

MESO

NTRB

NXTC

RBOT

SHPH

SLRX

TRVN

12 Health Care Stocks Moving In Friday's After-Market Session

Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Rockwell Med (RMTI – Research Report) yesterday. The company's shares opened today ...

Maxim Group Reaffirms Their Buy Rating on Rockwell Med (RMTI)

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on RMTI stock, giving a Buy rating on August 8. Ram Selvaraju has given h...

Rockwell Med Secures Buy Rating on Strong Financials and Strategic Growth Prospects

Rockwell Medical hits 52-week high after supply deal with Nipro

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med (RMTI – Research Report) and keeping the price target at $9.00. ...

Buy Rating Justified by Rockwell Medical's Growth Prospects and Strategic Partnerships

Rockwell Medical enters into product purchase agreement

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med (RMTI – Research Report), with a price targe...

Buy Rating for Rockwell Medical: Growth and Margin Expansion Through Strategic Partnerships and Operational Efficiencies

Rockwell Medical: The Turnaround Is Looking Real

Small-caps get a lift after Fed's jumbo rate cut; see top 20 names per SA Quant ratings

Small-caps get a lift after Fed's jumbo rate cut; see top 20 names in SA Quant ratings

Small-caps get a lift after Fed's jumbo rate cut: See top 20 names in SA Quant ratings

AMSC

AQST

AVDV

AVUV

BYRN

CALF

CURI

DAVE

DFAS

DFSV

FNDA

GASS

HMENF

HRTG

IGIC

NPRRF

PSIX

PSNL

SCHA

SLNCF

USAP

VIRC

Press Releases

Rockwell Medical Continues to Expand its Distribution Capabilities in Western United States

Rockwell Medical Announces First Quarter 2024 Results, Raises 2024 Guidance

Rockwell Medical Promotes Tim Chole to Chief Commercial Officer

Rockwell Medical to Release Second Quarter 2024 Results on Thursday, August 8, 2024

Rockwell Medical to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Rockwell Medical Launches Convenience Pack to Support Home Hemodialysis and Acute Dialysis Facilities

Rockwell Medical Reports Profitability on a Cash Flow and Adjusted EBITDA Basis in the Second Quarter of 2024

Rockwell Medical Enters into Multi-Million Dollar Distribution Agreement with Nipro Medical Corporation

Rockwell Medical Announces Product Purchase Agreement with Leading At-Home and Acute Care Dialysis Provider

Rockwell Medical Named a Fortune 'Best Workplaces in Manufacturing & Production'

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Rockwell Medical

Rockwell Medical (RMTI) Forecast

Rockwell Medical (NASDAQ:RMTI) Stock, Quote.Headers.trade-ideas